首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1529387

全球體內給藥設備市場 - 2024-2031

Global On-body Drug Delivery Devices Market - 2024-2031

出版日期: 2024年08月06日 | 出版商:

DataM Intelligence | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

2023年，全球體內給藥裝置市場規模達379億美元，預計2031年將達733億美元，2024-2031年預測期間複合年成長率為8.6%。

體內藥物輸送裝置是設計為佩戴在身體上以將藥物直接輸送給患者或將其他治療物質輸送到作用部位的醫療設備。這些裝置旨在透過皮膚、黏膜或其他身體表面釋放藥物，從而提供受控和有針對性的藥物輸送。

這些裝置包括各種形式，例如貼片、幫浦和注射器，可以附著在衣服下方或外面的身體上。這些設備的主要目的是提供持續和受控的藥物輸送，從而允許在預定時間精確給藥或連續輸注。

用於小分子藥物皮下給藥的體內給藥裝置的容量可達 3 ml。它被貼在身體上。典型的應用是幾個小時內的推注和基礎治療方案。這種貼片式裝置可皮下輸送大分子（生物製劑），專為定期需要一定總量的配製藥物的治療而設計。典型應用包括單株抗體 (mAb) 等蛋白質。

市場動態：

司機

慢性病發生率上升以及患者轉向先進的給藥系統

全球體內給藥裝置市場的需求是由多種因素所驅動的。關鍵因素之一是慢性病發病率的上升和患者轉向先進的藥物傳輸系統。

糖尿病、關節炎、高血壓和癌症等慢性病的盛行率不斷上升，是推動體內給藥裝置需求的主要因素。這些設備可實現精確劑量、提高依從性並減少治療反應的變異性，從而更有效地管理慢性病。

患者越來越喜歡體內藥物輸送裝置，因為它們比傳統藥物輸送方法更有優勢。這些優點包括更高的精度、更低的劑量增量、家庭使用功能、自動針插入和縮回、閉塞檢測以及標準玻璃藥筒的使用。準確靶向特定細胞或組織，同時最大限度地減少副作用和提高治療效果的能力正在推動這些先進藥物傳輸系統的採用。

此外，合作夥伴關係和協作以及產品發布和批准等行業策略的關鍵參與者將推動該市場的成長。例如，2023 年 3 月，Stevanato Group SpA 宣布與 Thermo Fisher Scientific 合作，將用於皮下給藥的完全整合的體內輸送系統平台推向市場。

此外，2023 年 4 月，美敦力 (Medtronic) 宣布美國食品藥物管理局 (FDA) 批准其 MiniMed 780G 系統，該系統配備 Guardian 4 感測器，在使用 Smart Guard 技術時無需進行指尖採血。這一里程碑標誌著唯一採用進餐檢測技術的系統獲得批准，該系統每 5 分鐘自動調整和校正血糖水平，以滿足基礎（背景）和推注（進餐時）胰島素需求。該系統提供胰島素，以幫助解決用戶偶爾忘記推注或低估膳食中碳水化合物含量的情況。

限制

設備和治療的高成本、針刺傷害和患者不適的風險、監管挑戰以及人們缺乏意識等因素預計將阻礙市場。

有關此報告的更多詳細資訊 - 索取樣本

On-body drug delivery devices are medical devices that are designed to be worn on the body to deliver medications directly to patients or other therapeutic substances to the site of action. These devices are designed to release drugs through the skin, mucous membranes, or other body surfaces, providing a controlled and targeted delivery of medication.

These devices include various forms such as patches, pumps, and injectors, which can be attached to the body either under or over clothing. The primary purpose of these devices is to provide sustained and controlled delivery of medications, allowing for precise dosing at predetermined times or continuous infusion.

The on-body drug delivery device for the subcutaneous administration of small-molecule drugs is available for volumes up to 3 ml. It is patched onto the body. Typical applications are bolus and basal regimens over several hours. This patched-on device delivers large molecules (biologics) subcutaneously and is designed for therapies that periodically require a certain total quantity of a formulated drug. Typical applications include proteins such as monoclonal antibodies (mAbs).

Market Dynamics: Drivers

Rise in incidences of chronic diseases & patients' shift toward advanced drug delivery systems

The demand for the global on-body drug delivery devices market is driven by multiple factors. One of the key factors is the rise in incidences of chronic diseases & patients' shift toward advanced drug delivery systems.

The increasing prevalence of chronic conditions such as diabetes, arthritis, hypertension, and cancer is a major factor driving the demand for on-body drug delivery devices. These devices enable more effective management of chronic diseases by allowing for precise dosing, improved adherence, and reduced variability in treatment response.

Patients are increasingly preferring on-body drug delivery devices due to their advantages over traditional drug delivery methods. These advantages include higher precision, lower dosing increments, home-use capabilities, automatic needle insertion and retraction, occlusion detection, and the use of standard glass cartridges. The ability to accurately target specific cells or tissues while minimizing side effects and increasing therapeutic efficacy is driving the adoption of these advanced drug delivery systems.

Moreover, key players in the industry strategies such as partnerships & collaborations, and product launches & approvals would propel this market growth. For instance, in March 2023, Stevanato Group S.p.A. announced its collaboration with Thermo Fisher Scientific to bring a fully integrated on-body delivery system platform for subcutaneous administration to the market.

Also, in April 2023, Medtronic announced the U.S. Food and Drug Administration (FDA) approval of its MiniMed 780G system with the Guardian 4 sensor requiring no finger sticks while in Smart Guard technology. This milestone marks the approval of the only system with meal detection technology that provides automatic adjustments and corrections to sugar levels every 5 minutes for both basal (background) and bolus (mealtime) insulin needs. The system provides insulin to help account for when users occasionally forget to bolus or underestimate the number of carbs in their meals.

Restraints

Factors such as the high costs of devices & treatment, the risk of needlestick injuries & patient discomfort, regulatory challenges, and lack of awareness among people, are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global on-body drug delivery devices market is segmented based on device type, molecule type, application, distribution channels, and region.

The wearable injectors segment accounted for approximately 62.8% of the global on-body drug delivery devices market share

The wearable injectors segment is expected to hold the largest market share over the forecast period. Wearable injection systems are drug-delivery devices that adhere to the body, automatically delivering set doses to the patient at optimal times. Wearable injection systems represent the natural evolution of chronic disease management. As wearable injection systems have emerged in response to these conditions, so has a completely new set of challenges regarding device design and testing.

Moreover, key players in the industry product launches and approvals help to drive this segment growth in the market. For instance, in February 2024, LTS LOHMANN Therapie-Systeme AG launched its UDENYCA on-body injector (OBI) utilizing the LTS Sorrel wearable drug delivery platform. UDENYCA (pegfilgrastim-cbqv) is a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

Also, in September 2023, Enable Injections, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI Injector (enFuse) for the subcutaneous delivery of EMPAVELI (pegcetacoplan), which is commercialized in the United States by Apellis Pharmaceuticals, Inc. for adults with paroxysmal nocturnal hemoglobinuria (PNH). The EMPAVELI Injector is a compact, wearable injector designed to streamline the self-administration experience with minimal disruption to patients' daily lives.

In addition, major players' innovative developments, investments, and mergers & acquisitions drive this segment's growth in the market. For instance, in January 2023, Eitan Medical opened a new manufacturing facility for a wearable drug delivery platform. The new manufacturing facility at its headquarters to support drug-delivery device production.

Similarly, in April 2023, LTS Lohmann acquired the Sorrel wearable injection device business headquartered in Netanya, Israel, a part of Eitan Medical Ltd.

Geographical Analysis

North America accounted for approximately 42.1% of the global on-body drug delivery devices market share

North America region is expected to hold the largest market share over the forecast period owing to the rising incidence of chronic diseases, demand for self-administration medications, and well-advanced healthcare infrastructure propelling the market growth in this region.

Moreover, a major number of key players' presence, technological advancements, and product launches & approvals drive the market growth. For instance, in February 2024, Tandem Diabetes Care, Inc. announced the United States commercial launch of its new Tandem Mobi, the world's smallest, durable automated insulin delivery system for people living with diabetes. The company has begun taking orders and shipping to eligible customers in the United States.

Also, in October 2022, after five years and two unsuccessful attempts, scPharmaceuticals finally pushed its on-body infusor for congestive heart failure across the FDA finish line. With the approval, Furoscix becomes the first self-administered, subcutaneous loop diuretic for those with worsening HF.

The Food and Drug Administration (FDA) approved Furoscix (furosemide injection) for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.

Market Segmentation

By Devices Type

Wearable Injectors
Infusion Pumps
Others

By Molecules Type

Small Molecule
Large Molecule

By Application

Cardiovascular Diseases
Cancer
Diabetes
Auto-immune Disease
Others

By Distribution Channel

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
South America
- Brazil
- Argentina
- The rest of South America
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Middle East and Africa

Competitive Landscape

The major global players in the on-body drug delivery devices market include Gerresheimer AG, NOVO Engineering, West Pharmaceutical Services, Inc., Enable Injections, Stevanato Group, LTS Lohmann Therapie-Systeme AG, BD, Coherus BioSciences, Inc., Tandem Diabetes Care, Inc, and Battelle among others.

Key Developments

In January 2024, Aptar Digital Health and Gerresheimer developed an integrated cancer therapy solution. By connecting Aptar Digital Health's proprietary SaMD platform with Gx SensAir, Gerresheimer's on-body device for the subcutaneous delivery of large biologics molecules, this integrated solution is intended to improve overall treatment adherence and clinical outcomes.
In December 2023, Stevanato Group introduced the new patented on-body delivery system Vertiva for several subcutaneous therapies. Designed to be adapted to different delivery profiles, the device facilitates the administration of biologics and small-molecule drugs.

Why Purchase the Report?

To visualize the global on-body drug delivery devices market segmentation based on device type, molecule type, application, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the on-body drug delivery devices market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.

The global on-body drug delivery devices market report would provide approximately 70 tables, 63 figures, and 184 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Devices Type
3.2. Snippet by Molecule Type
3.3. Snippet by Application
3.4. Snippet by Distribution Channels
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise in Incidences of Chronic Diseases & Patients' Shift Toward Advanced Drug Delivery Systems
  - 4.1.1.2. Increasing Demand for Biologics and Large-Volume Injections
- 4.1.2. Restraints
  - 4.1.2.1. High Cost for Devices & Treatment
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Devices Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices Type
- 6.1.2. Market Attractiveness Index, By Devices Type
6.2. Wearable Injectors *
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Infusion Pumps
6.4. Others

7. By Molecule Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
- 7.1.2. Market Attractiveness Index, By Molecule Type
7.2. Small Molecule *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Large Molecule

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Market Attractiveness Index, By Application
8.2. Cardiovascular Diseases *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cancer
8.4. Diabetes
8.5. Auto-immune Disease
8.6. Others

9. By Distribution Channels

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 9.1.2. Market Attractiveness Index, By Distribution Channels
9.2. Hospital Pharmacies *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Gerresheimer AG *
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. NOVO Engineering
12.3. West Pharmaceutical Services, Inc
12.4. Enable Injections
12.5. Stevanato Group
12.6. LTS Lohmann Therapie-Systeme AG
12.7. BD
12.8. Coherus BioSciences, Inc.
12.9. Tandem Diabetes Care, Inc
12.10. Battelle

LIST NOT EXHAUSTIVE